04:19 PM EDT, 03/17/2026 (MT Newswires) -- Trevi Therapeutics ( TRVI ) reported a Q4 loss late Tuesday of $0.06 per diluted share, narrowing from a loss of $0.11 a year earlier.
Analysts polled by FactSet expected a loss of $0.10.
The company ended the quarter with $188.3 million in cash, cash equivalents and marketable securities, providing a cash runway into 2028.